Associate Professor Xiaochao Ma, PhD received a grant from the NIH titled “Pharmacoenhancers for antiretroviral therapy: safety and future development”

The objectives of this application are to determine the mechanisms of liver toxicity associated with pharmacoenhancers for anti-HIV therapy, including ritonavir (RTV) and cobicistat (COBI), and to provide a mechanism-based guidance for development of the next generation of pharmacoenhancers with less liver toxicity.

Leave a comment